PDF herunterladen
Semin Liver Dis 2021; 41(02): 172-181
DOI: 10.1055/s-0041-1723032
Review Article

Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective

Beat Moeckli
1   Department of Visceral and Transplantation Surgery, University of Geneva Hospitals, Geneva, Switzerland
,
Pietro Majno
2   Epatocentro, Ospedale Regionale di Lugano, Lugano, Switzerland
,
Lorenzo A. Orci
1   Department of Visceral and Transplantation Surgery, University of Geneva Hospitals, Geneva, Switzerland
,
Andrea Peloso
1   Department of Visceral and Transplantation Surgery, University of Geneva Hospitals, Geneva, Switzerland
,
Christian Toso
1   Department of Visceral and Transplantation Surgery, University of Geneva Hospitals, Geneva, Switzerland
› Institutsangaben Funding Statement The authors received no specific funding for this work.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

For patients with early-stage hepatocellular carcinoma (HCC), liver transplantation offers the best chance of cure. Over the past two decades, selection criteria to determine eligibility for liver transplantation have been constantly refined but a fair allocation strategy of liver grafts to HCC patients remains challenging. In Europe, over a dozen transplantation networks apply different liver transplantation criteria for HCC patients. In this review, we explore and compare candidate selection and liver graft allocation strategies for patients with HCC with a European perspective and discuss the ethical and technical challenges involved. In addition, we suggest possible paths for future improvement such as transitioning from fixed selection and allocation criteria to a more flexible model of benefit, which includes criteria concerning the graft, response to treatment, the biology of the tumor, and other relevant recipient factors.

Keywords

liver transplantation - HCC - allocation - transplant benefit - selection


Publikationsverlauf

Artikel online veröffentlicht:
06. Mai 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Mehta N, Guy J, Frenette CT. et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study. Clin Gastroenterol Hepatol 2018; 16 (06) 955-964
    CrossrefPubMedGoogle Scholar
  • 2 Mazzaferro V, Sposito C, Zhou J. et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018; 154 (01) 128-139
    CrossrefPubMedGoogle Scholar
  • 3 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 4 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    Google Scholar
  • 5 Mazzaferro V, Llovet JM, Miceli R. et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 6 Toso C, Trotter J, Wei A. et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14 (08) 1107-1115
    CrossrefPubMedGoogle Scholar
  • 7 Wee A. Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations. Pathol Res Int 2011; 2011: 587936
    PubMedGoogle Scholar
  • 8 Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380 (15) 1450-1462
    CrossrefPubMedGoogle Scholar
  • 9 European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
    CrossrefPubMedGoogle Scholar
  • 10 Duvoux C, Roudot-Thoraval F, Decaens T. et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143 (04) 986.e3-994.e3 ; quiz e14–15
    CrossrefPubMedGoogle Scholar
  • 11 Toso C, Meeberg G, Hernandez-Alejandro R. et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015; 62 (01) 158-165
    CrossrefPubMedGoogle Scholar
  • 12 Luo P, Yin P, Hua R. et al. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology 2018; 67 (02) 662-675
    CrossrefPubMedGoogle Scholar
  • 13 Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep 2017; 7 (01) 12870
    CrossrefPubMedGoogle Scholar
  • 14 Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127 (05, Suppl 1): S108-S112
    CrossrefPubMedGoogle Scholar
  • 15 Giannini EG, Marenco S, Borgonovo G. et al; Italian Liver Cancer (ITA.LI.CA) group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012; 56 (04) 1371-1379
    CrossrefPubMedGoogle Scholar
  • 16 Otto G, Schuchmann M, Hoppe-Lotichius M. et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?. J Hepatol 2013; 59 (02) 279-284
    CrossrefPubMedGoogle Scholar
  • 17 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 18 Majno PE, Adam R, Bismuth H. et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226 (06) 688-701 , discussion 701–703
    CrossrefPubMedGoogle Scholar
  • 19 Tsochatzis E, Garcovich M, Marelli L. et al. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int 2013; 33 (06) 944-949
    CrossrefPubMedGoogle Scholar
  • 20 Clavien P-A, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A. OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22
    CrossrefPubMedGoogle Scholar
  • 21 NHSBT. POLICY POL195/11: Liver transplantation: selection criteria and recipient registration. 2019 . Accessed September 17, 2020 at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/9440/pol195_7-liver-selection-policy.pdf
    PubMedGoogle Scholar
  • 22 Rodríguez-Perálvarez M, Gómez-Bravo MA, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J. Spanish Society of Liver Transplantation (SETH)**. Expanding indications of liver transplantation in Spain: consensus statement and recommendations by the Spanish Society of Liver Transplantation. Transplantation 2020; (e-pub ahead of print) DOI: 10.1097/TP.0000000000003281.
    CrossrefPubMedGoogle Scholar
  • 23 Pommergaard HC, Rostved AA, Adam R. et al; European Liver and Intestine Transplant Association (ELITA). Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int 2018; 31 (05) 531-539
    CrossrefPubMedGoogle Scholar
  • 24 Neuberger J, Thorburn D. MELD—Moving steadily towards equality, equity, and fairness. Liver Transpl 2005; 11: 585-587
    CrossrefPubMedGoogle Scholar
  • 25 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31 (04) 864-871
    CrossrefPubMedGoogle Scholar
  • 26 Kamath PS, Wiesner RH, Malinchoc M. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (02) 464-470
    CrossrefPubMedGoogle Scholar
  • 27 Luo X, Leanza J, Massie AB. et al. MELD as a metric for survival benefit of liver transplantation. Am J Transplant 2018; 18 (05) 1231-1237
    CrossrefPubMedGoogle Scholar
  • 28 Lee J, Kim DG, Lee JY. et al. Impact of model for end-stage liver disease score-based allocation system in Korea: a nationwide study. Transplantation 2019; 103 (12) 2515-2522
    CrossrefPubMedGoogle Scholar
  • 29 Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013; 59 (02) 367-374
    CrossrefPubMedGoogle Scholar
  • 30 Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006; 12 (12, Suppl 3): S85-S87
    CrossrefPubMedGoogle Scholar
  • 31 Navasa M, Bruix J. Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models. Hepatology 2010; 51 (01) 12-15
    CrossrefPubMedGoogle Scholar
  • 32 Sharma P, Harper AM, Hernandez JL. et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006; 6 (08) 1957-1962
    CrossrefPubMedGoogle Scholar
  • 33 Heimbach JK. United States liver allocation. Curr Opin Organ Transplant 2020; 25 (02) 104-109
    CrossrefPubMedGoogle Scholar
  • 34 Uehlinger NB, Beyeler F, Weiss J, Marti HP, Immer FF. Organ transplantation in Switzerland: impact of the new transplant law on cold ischaemia time and organ transports. Swiss Med Wkly 2010; 140 (15–16): 222-227
    PubMedGoogle Scholar
  • 35 Langer RM, Cohen B, Rahmel A. History of eurotransplant. Transplant Proc 2012; 44 (07) 2130-2131
    CrossrefPubMedGoogle Scholar
  • 36 Eurotransplant, Chapter 5. Eurotransplant liver allocation system. 2019 . Accessed September 17, 2020 at: https://www.eurotransplant.org/wp-content/uploads/2020/01/H5-ELAS-MELD.pdf
    PubMedGoogle Scholar
  • 37 Jochmans I, van Rosmalen M, Pirenne J, Samuel U. Adult liver allocation in Eurotransplant. Transplantation 2017; 101 (07) 1542-1550
    CrossrefPubMedGoogle Scholar
  • 38 Umgelter A, Hapfelmeier A, Kopp W, van Rosmalen M, Rogiers X, Guba M. Eurotransplant Liver Advisory Committee. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. Liver Transpl 2017; 23 (10) 1256-1265
    CrossrefPubMedGoogle Scholar
  • 39 Ishaque T, Massie AB, Bowring MG. et al. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. Am J Transplant 2019; 19 (02) 564-572
    CrossrefPubMedGoogle Scholar
  • 40 Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015; 61 (01) 285-291
    CrossrefPubMedGoogle Scholar
  • 41 IRODaT. International Online Registry for Organ Donation and Transplantation. 2019 . Accessed September 17, 2020 at: https://www.irodat.org/
    PubMedGoogle Scholar
  • 42 Matesanz R, Domínguez-Gil B, Coll E, Mahíllo B, Marazuela R. How Spain reached 40 deceased organ donors per million population. Am J Transplant 2017; 17 (06) 1447-1454
    CrossrefPubMedGoogle Scholar
  • 43 Organizacion nacional de trasplantes, Actividad de Donación y Trasplante Hepático e Intestinal 2019, Accessed: 21.01.2021, http://www.ont.es/infesp/Memorias/Actividad%20de%20Donaci%C3%B3n%20y%20Trasplante%20Hep%C3%A1tico%20e%20Intestinal%202019.pdf
    PubMed
  • 44 de la Rosa G, Fondevila C, Navasa M. Liver transplantation in Spain. Liver Transpl 2016; 22 (09) 1259-1264
    CrossrefPubMedGoogle Scholar
  • 45 Llovet JM, Fuster J, Bruix J. Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (02, Suppl 1): S115-S120
    CrossrefPubMedGoogle Scholar
  • 46 Pardo F, Pons JA, Briceño J. en nombre de la Sociedad Española de Trasplante Hepático. V Consensus Meeting of the Spanish Society for Liver Transplant on high-risk recipients, immunosupression scenarios and management of hepatocarcinoma on the transplant waiting list. Cir Esp 2015; 93 (10) 619-637
    CrossrefPubMedGoogle Scholar
  • 47 Agence de la biomedicine. Activité de greffe hépatique 2019, Accessed: 21.01.2021, https://rams.agence-biomedecine.fr/greffe-hepatique-0
    PubMed
  • 48 Amin MB, Greene FL, Edge SB. et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67 (02) 93-99
    CrossrefPubMedGoogle Scholar
  • 49 Durand F, Antoine C, Soubrane O. Liver transplantation in France. Liver Transpl 2019; 25 (05) 763-770
    CrossrefPubMedGoogle Scholar
  • 50 Angelico M, Cillo U, Fagiuoli S. et al; Liver Match Investigators. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43 (02) 155-164
    CrossrefPubMedGoogle Scholar
  • 51 De Carlis L, Di Sandro S, Centonze L. et al. Liver-allocation policies for patients affected by HCC in Europe. Curr Transplant Rep 2016; 3 (04) 313-318
    CrossrefPubMedGoogle Scholar
  • 52 Cillo U, Burra P, Mazzaferro V. et al; I-BELT (Italian Board of Experts in the Field of Liver Transplantation). A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “blended principle model”. Am J Transplant 2015; 15 (10) 2552-2561
    CrossrefPubMedGoogle Scholar
  • 53 Vitale A, Volk ML, De Feo TM. et al; Liver Transplantation North Italy Transplant program (NITp) working group. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014; 60 (02) 290-297
    CrossrefPubMedGoogle Scholar
  • 54 Sistema Informativo dei Trapianti, Name: Donazioni, trapianti, liste di attesa, Accessed: 21.01.2021, https://trapianti.sanita.it/statistiche/attivita/2020_F_ATTIVITA_ORGANI_DX-TX.pdf
    PubMed
  • 55 NHSBT. Annual report on liver transplantation for 2018/2019. 2019 . Accessed September 17, 2020 at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/16782/nhsbt-liver-transplantation-annual-report-2018-19.pdf
    PubMedGoogle Scholar
  • 56 NHSBT. Policy POL196/7 deceased donor liver distribution and allocation. 2019 . Accessed September 17, 2020 at: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/17449/liver-allocation-policy-pol196.pdf
    PubMedGoogle Scholar
  • 57 Surgical Informatics, University of Edinburgh, Name: Transplant Benefit Score Calculator, Accessed: 21.01.2021, https://transplantbenefit.org/
    PubMed
  • 58 Orci LA, Lacotte S, Oldani G. et al. Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. Br J Surg 2016; 103 (04) 417-426
    CrossrefPubMedGoogle Scholar
  • 59 Fosby B, Melum E, Bjøro K. et al. Liver transplantation in the Nordic countries - An intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol 2015; 50 (06) 797-808
    CrossrefPubMedGoogle Scholar
  • 60 Dueland S, Syversveen T, Solheim JM. et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 2020; 271 (02) 212-218
    CrossrefPubMedGoogle Scholar
  • 61 Pomfret EA, Washburn K, Wald C. et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16 (03) 262-278
    CrossrefPubMedGoogle Scholar
  • 62 Toso C, Majno P, Berney T, Morel P, Mentha G, Combescure C. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int 2014; 27 (07) 686-695
    CrossrefPubMedGoogle Scholar
  • 63 Schaubel DE, Guidinger MK, Biggins SW. et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9 (4, Pt 2): 970-981
    CrossrefPubMedGoogle Scholar
  • 64 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach. Hepatology 2016; 63 (05) 1707-1717
    CrossrefPubMedGoogle Scholar
  • 65 Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P. Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant 2014; 14 (10) 2221-2227
    CrossrefPubMedGoogle Scholar
  • 66 Gimson A. Development of a UK liver transplantation selection and allocation scheme. Curr Opin Organ Transplant 2020; 25 (02) 126-131
    CrossrefPubMedGoogle Scholar
  • 67 Lai Q, Vitale A, Iesari S. et al; European Hepatocellular Cancer Liver Transplant Study Group. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology 2017; 66 (06) 1910-1919
    CrossrefPubMedGoogle Scholar
  • 68 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019; 1 (05) 377-391
    CrossrefPubMedGoogle Scholar
  • 69 Halazun KJ, Tabrizian P, Najjar M. et al. Is it time to abandon the Milan criteria?: results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies. Ann Surg 2018; 268 (04) 690-699
    CrossrefPubMedGoogle Scholar
  • 70 Eurotransplant. Eurotransplant Statistics Report Library. 2020 . Accessed September 17, 2020 at: https://statistics.eurotransplant.org/
    PubMedGoogle Scholar
  • 71 Neuberger J. Liver transplantation in the United Kingdom. Liver Transpl 2016; 22 (08) 1129-1135
    CrossrefPubMedGoogle Scholar
  • 72 Registry NLT. The Nordic Liver Transplant Registry (NLTR) Annual report 2018. 2018 . Accessed September 17, 2020 at: http://www.scandiatransplant.org/members/nltr/TheNordicLiverTransplantRegistryANNUALREPORT2018.pdf
    PubMedGoogle Scholar
  • 73 Czerwiński J, Lewandowska D, Małkowski P, Danielewicz R. Liver donation and transplantation in Poland: numbers, indicators, and trends. Transplant Proc 2016; 48 (05) 1341-1346
    CrossrefPubMedGoogle Scholar
  • 74 Poltransplant, Poltransplant Information Bulletin, Accessed: 21.01.2021, https://www.poltransplant.org.pl/aktual.html
    PubMed
  • 75 Swisstransplant, Annual Report Swisstransplant 2018, Accessed: 21.01.2021, https://www.swisstransplant.org/fileadmin/user_upload/Swisstransplant/Jahresbericht/Jahresbericht_und_Grafiken_2018/Swisstransplant_Jahresbericht_2018.pdf
    PubMed
  • 76 Swisstransplant, Monthly Reports: Key Figures on Organ Donation and Organ Donation, Accessed: 21.01.2021, https://www.swisstransplant.org/en/information-material/for-professionals/information-about-the-coronavirus/monthly-reports/
    PubMed
  • 77 Popescu I, Ionescu M, Braşoveanu V. et al. The Romanian National Program for Liver Transplantation - 852 procedures in 815 patients over 17 years (2000-2017): a continuous evolution to success. Chirurgia (Bucur) 2017; 112 (03) 229-243
    CrossrefPubMedGoogle Scholar